Gynica

Gynica is a biotech company driven to improve the lives of hundreds of millions of women worldwide suffering from Endometriosis by providing safe, effective, non-hormonal, intra-vaginal therapeutic solutions through its proprietary IntraVag© technology—a non-invasive, self-administered drug delivery platform. Endometriosis is a chronic and debilitating condition affecting at least 10%—more than 200 million—of women and girls of reproductive age worldwide, severely impacting their quality of life and overall well-being. Characterized by the abnormal growth of endometrial tissue outside the uterus, Endometriosis can cause a range of distressing symptoms, including intense pelvic pain, painful intercourse, menstrual irregularities, and infertility. Increasing awareness, improved diagnostic techniques, and the prevalence of the condition have given rise to the growing demand for safe and effective therapies in an underserved market—with a potential global annual market worth of $180 billion. Gynica is owned by Asana Bio Group, a holding company specializing in life sciences innovations.

Gynica has raised $4M in total funding across 2 rounds. The company is currently at the Seed stage. Key investors include Undisclosed Investor(s).

Gynica was founded in 2019 by Yotam Hod (CEO & Co-Founder).

Gynica operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, Drugs Discovery & Development, with core technologies in Materials & Substances, Raw Materials, Biologicals, Herbals, Molecules. Target customers: Healthcare & Life Sciences, Medical Devices Industry, Medical Products, Life Sciences, Pharmaceuticals, Biotechnology, Consumers, Demographics & Family, Women.

Gynica is based in Israel.